Pre-exposure prophylaxis (PrEP) is one of the most powerful tools we have to prevent HIV acquisition. Last week the Centers for Disease Control and Prevention (CDC) published its updated Clinical Practice Guideline for Preexposure Prophylaxis for HIV Prevention and Clinical Providers Supplement.
The overall goals of the revisions are to update existing guidance using the current evidence base, incorporate recent and potential FDA actions on PrEP medications, clarify specific aspects of clinical care, and improve usability and increase implementation of the guideline.
Key revisions include:
- A new recommendation for providers to inform all sexually active adults and adolescents about PrEP.
- A new recommendation for providers to prescribe PrEP to anyone who requests it.
- A new section on prescribing bimonthly intramuscular injections of cabotegravir (CAB) for sexually active men and women who could benefit from PrEP, pending FDA data review and potential regulatory action.
Please join us on Tuesday, December 14, 2021, at 4:30 PM ET/1:30 PT for a webinar featuring CDC Division of HIV Prevention’s Director Demetre Daskalakis, MD, MPH, and Clinical Biomedical Prevention Activity Lead Dawn K. Smith, MD, MS, MPH. They will discuss the updated guideline and supplement, and CDC’s commitment to work with providers, partners, and communities across the country to increase implementation of the guideline and uptake of PrEP. Both will help to reach our shared goal of reducing new HIV infections by 90% by 2030.
Drs. Smith and Daskalakis will answer questions following the presentation.
Please click on the link below to access the registration page for this event. Space is provided there to ask any questions you might have in advance.